GEN Exclusives

More »

GEN News Highlights

More »
Jul 19, 2007

Glenmark Buys Rights to Two mAbs from Chromos

  • Glenmark Pharmaceuticals completed the purchase of two NBEs from Chromos Molecular Systems. CHR-1103 and CHR-1201 are humanized mAbs.

    Under the terms of the transaction, Glenmark bought all rights to the products as well as rights to use Chromos' ACE System technology for cell-line development for use with respect to CHR-1103 and CHR-1201. Glenmark holds the worldwide rights for further development, registration, and commercialization of these products.

    CHR-1103 and CHR-1201 are part of a validated class of drugs known as SAMIs, or selective adhesion molecule inhibitors. CHR-1103 is an anti-inflammatory agent with a novel mechanism of action, being developed initially to treat acute multiple sclerosis. Glenmark plans to initiate Phase I trials in 2008.

    CHR-1201 is an antithrombolytic, which Glenmark plans to develop initially to treat acute stroke. The company expects to start Phase I on CHR-1201 by March 2009.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Should the CDC Director Resign?

Do you think the CDC chief should resign?